Telomere shortening in mucosa surrounding the tumor: Biosensor of field cancerization and prognostic marker of mucosal failure in head and neck squamous cell carcinoma

Oral Oncology

Volumn 51, Issue 5, 2015, Pages 500-507

  Boscolo Rizzo, Paolo ^a   Rampazzo, Enrica ^a   Perissinotto, Egle ^a   Piano, Maria Assunta ^a   Giunco, Silvia ^b   Baboci, Lorena ^a   Spinato, Giacomo ^c   Spinato, Roberto ^d   Tirelli, Giancarlo ^c   Da Mosto, Maria Cristina ^a   Del Mistro, Annarosa ^b   De Rossi, Anita ^a,c  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d OSPEDALE DELL'ANGELO   (Italy)

Author keywords

Field cancerization; Head and neck cancer; Human papilloma virus; Local relapse; Molecular biology; Survival; Telomerase reverse transcriptase; Telomeres; TERT

Indexed keywords

TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOSENSOR; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FEMALE; GENETIC TRANSCRIPTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MUCOSA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TELOMERE; TELOMERE SHORTENING; GENETIC PROCEDURES; HEAD AND NECK TUMOR; METABOLISM; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA;

BIOMARKERS, TUMOR; BIOSENSING TECHNIQUES; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MUCOUS MEMBRANE; PROGNOSIS; TELOMERASE; TELOMERE;

EID: 84933670812     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2015.02.100     Document Type: Article

References (53)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
2. Leemans CR, Braakhuis BJ, Brakenhoff RH. The molecular biology of head and neck cancer. Nat Rev Cancer 2011;11:9-22.
3. Pulte D, Brenner H. Changes in survival in head and neck cancers in the Late 20th and Early 21st Century: a period analysis. Oncologist 2010;15:994-1001.
4. León X, Quer M, Diez S, Orús C, López-Pousa A, Burgués J. Second neoplasm in patients with head neck cancer. Head Neck 1999;21:204-10.
5. Braakhuis BJ, Brakenhoff RH, Leemans CR. Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. Ann Oncol 2012;23(Suppl 10):x173-7.
6. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Van Der Wal JE, Snow GB, Leemans CR, et al. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol 2002;161:1051-60.
7. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Kummer JA, Leemans CR, Braakhuis BJ. Genetically altered fields as origin of locally recurrent head and neck cancer: a retrospective study. Clin Cancer Res 2004;10:3607-13.
8. van Houten VM, Leemans CR, Kummer JA, Dijkstra J, Kuik DJ, van den Brekel MW, et al. Molecular diagnosis of surgical margins and local recurrence in head and neck cancer patients: a prospective study. Clin Cancer Res 2004;10:3614-20.
9. Deganello A, Franchi A, Sardi I, Pignataro L, Leemans CR, Gallo O. Genetic alterations between primary head and neck squamous cell carcinoma and recurrence after radiotherapy: recurrence, genetically related cancer, or second primary? Cancer 2010;116:1291-7.
10. Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997;277(5328):955-9.
11. Blasco MA. Telomeres and human disease: ageing, cancer and beyond. Nat Rev Genet 2005;6:611-22.
12. Rampazzo E, Bertorelle R, Serra L, Terrin L, Candiotto C, Pucciarelli S, et al. Relationship between telomere shortening, genetic instability, and site of tumor origin in colorectal cancers. Br J Cancer 2010;102:1300-5.
13. Bertorelle R, Rampazzo E, Pucciarelli S, Nitti D, De Rossi A. Telomeres, telomerase and colorectal cancer. World J Gastroenterol 2014;20:1940-50.
14. Calcagnile O, Gisselsson D. Telomere dysfunction and telomerase activation in cancer-a pathological paradox? Cytogenet Genome Res 2007;118:270-6.
15. Raynaud CM, Sabatier L, Philipot O, Olaussen KA, Soria JC. Telomere length, telomeric proteins and genomic instability during the multistep carcinogenic process. Crit Rev Oncol Hematol 2008;66:99-117.
16. Dolcetti R, De Rossi A. Telomere/telomerase interplay in virus-driven and virus-independent lymphomagenesis: pathogenic and clinical implications. Med Res Rev 2012;32:233-53.
17. Kong CM, Lee XW, Wang X. Telomere shortening in human diseases. FEBS J 2013;280:3180-93.
18. Patel MM, Parekh LJ, Jha FP, Sainger RN, Patel JB, Patel DD, et al. Clinical usefulness of telomerase activation and telomere length in head and neck cancer. Head Neck 2002;24:1060-7.
19. Gordon KE, Ireland H, Roberts M, Steeghs K, McCaul JA, MacDonald DG, et al. High levels of telomere dysfunction bestow a selective disadvantage during the progression of human oral squamous cell carcinoma. Cancer Res 2003;63:458-67.
20. Sainger RN, Telang SD, Shukla SN, Patel PS. Clinical significance of telomere length and associated proteins in oral cancer. Biomark Insights 2007;2:9-19.
21. McCaul JA, Gordon KE, Minty F, Fleming J, Parkinson EK. Telomere dysfunction is related to the intrinsic radio-resistance of human oral cancer cells. Oral Oncol 2008;44:261-9.
22. Sainger RN, Shah FD, Telang SD, Shah PM, Patel PS. Telomere attrition and telomerase activity are associated with GSTM1 polymorphism in oral cancer. Cancer Biomark 2009;5:189-95.
23. Tang T, Zhou FX, Lei H, Yu HJ, Xie CH, Zhou YF, et al. Increased expression of telomere-related proteins correlates with resistance to radiation in human laryngeal cancer cell lines. Oncol Rep 2009;21:1505-9.
24. Aida J, Izumo T, Shimomura N, Nakamura K, Ishikawa N, Matsuura M, et al. Telomere lengths in the oral epithelia with and without carcinoma. Eur J Cancer 2010;46:430-8.
25. Aida J, Kobayashi T, Saku T, Yamaguchi M, Shimomura N, Nakamura K, et al. Short telomeres in an oral precancerous lesion: Q-FISH analysis of leukoplakia. J Oral Pathol Med 2012;41:372-8.
26. Mao L, El-Naggar AK, Fan YH, Lee JS, Lippman SM, Kayser S, et al. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res 1996;56:5600-4.
27. Curran AJ, Gullane PJ, Irish J, Macmillan C, Freeman J, Kamel-Reid S. Telomerase activity is upregulated in laryngeal squamous cell carcinoma. Laryngoscope 2000;110:391-6.
28. Zhang S, Dong M, Teng X, Chen T. Quantitative assay of telomerase activity in head and neck squamous cell carcinoma and other tissues. Arch Otolaryngol Head Neck Surg 2001;127:581-5.
29. Kim HR, Christensen R, Park NH, Sapp P, Kang MK, Park NH. Elevated expression of hTERT is associated with dysplastic cell transformation during human oral carcinogenesis in situ. Clin Cancer Res 2001;7:3079-86.
30. Luzar B, Poljak M, Marin IJ, Gale N. Telomerase reactivation is an early event in laryngeal carcinogenesis. Mod Pathol 2003;16:841-8.
31. Liao CT, Tung-Chieh Chang J, Wang HM, Chen IH, Lin CY, Chen TM, et al. Telomerase as an independent prognostic factor in head and neck squamous cell carcinoma. Head Neck 2004;26:504-12.
32. Chen HH, Yu CH, Wang JT, Liu BY, Wang YP, Sun A, et al. Expression of human telomerase reverse transcriptase (hTERT) protein is significantly associated with the progression, recurrence and prognosis of oral squamous cell carcinoma in Taiwan. Oral Oncol 2007;43:122-9.
33. Chen M, Yang B, Zhang X. Effects of telomerase activity on carcinogenesis and survival in laryngeal carcinoma. J Int Med Res 2008;36:336-42.
34. Kunická Z, Mucha I, Fajkus J. Telomerase activity in head and neck cancer. Anticancer Res 2008;28:3125-9.
35. Liu Y, Dong XL, Tian C, Liu HG. Human telomerase RNA component (hTERC) gene amplification detected by FISH in precancerous lesions and carcinoma of the larynx. Diagn Pathol 2012;7:34.
36. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.
37. Baboci L, Boscolo-Rizzo P, Holzinger D, Bertorelle R, Biasini L, Michel A, et al. Evidence of the causal role of human papillomavirus type 58 in an oropharyngeal carcinoma. Virol J 2013;12(10):334.
38. Rampazzo E, Bertorelle R, Serra L, Terrin L, Candiotto C, Pucciarelli S, et al. Relationship between telomere shortening, genetic instability, and site of tumor origin in colorectal cancers. Br J Cancer 2010;102:1300-5.
39. Rampazzo E, Bonaldi L, Trentin L, Visco C, Keppel S, Giunco S, et al. Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. Haematologica 2012;97:56-63.
40. O'Callaghan N, Dhillon V, Thomas P, Fenech M. A quantitative real-time PCR method for absolute telomere length. Biotechniques 2008;44:807-9.
41. Boulay JL, Reuter J, Ritschard R, Terracciano L, Herrmann R, Rochlitz C. Gene dosage by quantitative real-time PCR. Biotechniques 1999;27(228-230):232.
42. Terrin L, Rampazzo E, Pucciarelli S, Agostini M, Bertorelle R, Esposito G, et al. Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clin Cancer Res 2008;14:7444-51.
43. Bertorelle R, Briarava M, Rampazzo E, Biasini L, Agostini M, Maretto I, et al. Telomerase is an independent prognostic marker of overall survival in patients with colorectal cancer. Br J Cancer 2013;108:278-84.
44. Roesch-Ely M, Nees M, Karsai S, Ruess A, Bogumil R, Warnken U, et al. Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene 2007;26:54-64.
45. Van der Vorst S, Dekairelle AF, Weynand B, Hamoir M, Gala JL. Assessment of p53 functional activity in tumor cells and histologically normal mucosa from patients with head and neck squamous cell carcinoma. Head Neck 2012;34:1542-50.
46. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990;346:866-8.
47. Gertler R, Rosenberg R, Stricker D, Friederichs J, Hoos A, Werner M, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol 2004;22:1807-14.
48. Escher A, Piotet E, Waridel F, Iggo R, Monnier P. P53 Mutation in histologically normal mucosa of the aero-digestive tract is not a marker of increased risk for second primary carcinoma in head and neck cancer patients. Eur Arch Otorhinolaryngol 2009;266:547-51.
49. Hohaus S, Cavallo S, Bellacosa A, Genuardi M, Galli J, Cadoni G, et al. Telomerase activity in human laryngeal squamous cell carcinomas. Clin Cancer Res 1996;2:1895-900.
50. Artandi SE, DePinho RA. Telomeres and telomerase in cancer. Carcinogenesis 2010;31:9-18.
51. Van Doorslaer K, Burk RD. Association between hTERT activation by HPV E6 proteins and oncogenic risk. Virology 2012;433:216-9.
52. Kumar SK, Zain RB, Ismail SM, Cheong SC. Human telomerase reverse transcriptase expression in oral carcinogenesis: a preliminary report. J Exp Clin Cancer Res 2005;24:639-46.
53. Bektas Kayhan K. Role of Inflammation in Oral Squamous Cell Carcinoma. In: Xiaoming Li (Ed.), Squamous Cell Carcinoma, 2012. ISBN: 978-953-51-0024-9.